Alitretinoin oral - Stiefel Laboratories

Drug Profile

Alitretinoin oral - Stiefel Laboratories

Alternative Names: Alitretinoin - Basilea; BAL4079; Cehado; Once-daily oral alitretinoin - Basilea; Toctino

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Basilea Pharmaceutica; Stiefel Laboratories
  • Class Antineoplastics; Keratolytics; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Eczema
  • Discontinued Palmoplantar pustulosis; Systemic lupus erythematosus

Most Recent Events

  • 21 Jan 2016 Discontinued - Phase-III for Eczema in USA (PO)
  • 23 Nov 2015 Stiefel acquires distribution rights to Alitretinoin in Europe
  • 13 Mar 2015 No recent reports on development identified - Registered for Eczema in Belgium, Luxembourg and Lithuania (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top